Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review
Nutrients · 11.05.2023 · 15 (10) · 2275
DOI: 10.3390/nu15102275 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 11.05.2023. Verfasst von Neeraja Recharla und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, The University of Texas Medical Branch, 301 University Blvd, 4.106 Basic Science Building, Galveston, TX 77555-0655,…. Hauptthemen laut MEDLINE: Crohn Disease, Colitis, Ulcerative, Gastrointestinal Microbiome, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 219-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, United States Department of Defense, National Institute of Health.
Abstract (Originalsprache)
Background and objective: Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is a chronic inflammatory disorder characterized by aberrant immune responses and compromised barrier function in the gastrointestinal tract. IBD is associated with altered gut microbiota and their metabolites in the colon. Butyrate, a gut microbial metabolite, plays a crucial role in regulating immune function, epithelial barrier function, and intestinal homeostasis. In this review, we aim to present an overview of butyrate synthesis and metabolism and the mechanism of action of butyrate in maintaining intestinal homeostasis and to discuss the therapeutic implications of butyrate in IBD.
Methods
We searched the literature up to March 2023 through PubMed, Web of Science, and other sources using search terms such as butyrate, inflammation, IBD, Crohn’s disease, and ulcerative colitis. Clinical studies in patients and preclinical studies in rodent models of IBD were included in the summary of the therapeutic implications of butyrate.
Results
Research in the last two decades has shown the beneficial effects of butyrate on gut immune function and epithelial barrier function. Most of the preclinical and clinical studies have shown the positive effect of butyrate oral supplements in reducing inflammation and maintaining remission in colitis animal models and IBD patients. However, butyrate enema showed mixed effects. Butyrogenic diets, including germinated barley foodstuff and oat bran, are found to increase fecal butyrate concentrations and reduce the disease activity index in both animal models and IBD patients.
Conclusions
The current literature suggests that butyrate is a potential add-on therapy to reduce inflammation and maintain IBD remission. Further clinical studies are needed to determine if butyrate administration alone is an effective therapeutic treatment for IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, The University of Texas Medical Branch, 301 University Blvd, 4.106 Basic Science Building, Galveston, TX 77555-0655, USA.
Förderung
- NIDDK NIH HHS
- United States Department of Defense
- National Institute of Health
Zitieren
APA
Recharla, N., Geesala, R., & Shi, X. Z. (2023). Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review. Nutrients, 15(10), 2275. https://doi.org/10.3390/nu15102275
Vancouver
Recharla N, Geesala R, Shi XZ. Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review. Nutrients. 2023;15(10):2275. doi:10.3390/nu15102275
BibTeX
@article{Recharla2023,
author = {Recharla, Neeraja and Geesala, Ramasatyaveni and Shi, Xuan-Zheng},
title = {Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {10},
pages = {2275},
doi = {10.3390/nu15102275}
}
EUVIMED